INTRODUCTION {#s1}
============

Autism spectrum disorders (ASD) is a neurodevelopmental syndrome characterized by various degrees of social impairment, deficits in language and communication, and repetitive patterns of behavior \[[@R1], [@R2]\], but the underlying mechanisms remain to be elucidated. The reported prevalence of ASD has increased dramatically over time to approximately 100/10,000 (1%) today \[[@R3], [@R4]\], affecting the lives of 700,000 people and costing £32 billion each year in the UK \[[@R5]\]. The influence of prenatal exposures on development of ASD is gradually recognized, since substantial advances have been achieved in understanding the neurodevelopmental consequences of intrauterine challenges \[[@R6]\].

Hypertensive disorders of pregnancy (HDP) is a complex multisystem disorder, encompassing (1) gestational hypertension, (2) chronic hypertension complicating pregnancy (CHP), (3) pre-eclampsia and eclampsia \[[@R7]\], which can lead to severe maternal and fetal morbidity and even mortality \[[@R8]\]. Numerous studies have shown that fetal exposed to HDP had increased susceptibility to multiple neurodevelopmental disorders such as cognitive impairment \[[@R9]\] , depression \[[@R10]\], schizophrenia \[[@R11]\], and even elevated lifetime risks for stroke \[[@R12]\]. Ratsep et al. \[[@R13]\] reported that offspring of pre-eclamptic pregnancies exhibited altered brain structural and vascular anatomy as enlarged brain regional volumes of the cerebellum was detected by magnetic resonance imaging, which shared similarities with those seen in ASD. It is demonstrated that pregnancies affected by pre-eclampsia are correlated with an exaggerated immune responses, creating a chronic and uncontrolled state of inflammation \[[@R14], [@R15]\]. Epidemiological studies suggest that maternal infections (such as parasitic, bacterial and viral infection) \[[@R16]\] and autoimmune disorders (such as rheumatoid arthritis, asthma, systemic lupus erythematosis) \[[@R17]\], all of which lead to elevated immune responses, have been confirmed as independent risk factors for ASD \[[@R18]\].

Although a number of clinical studies \[[@R19]--[@R38]\] have been conducted to explore the undetermined association between HDP and ASD, the results of investigations were rather heterogeneous without collectively comparison. For instance, Walker et al. \[[@R26]\] observed that the children with ASD were twice as likely to have been exposed in utero to pre-eclampsia with controls, while Langridge et al. \[[@R36]\] failed to demonstrate statistically significant association between them. To determine whether all recent published epidemiologic studies, in combination, support an association between maternal HDP and the risk of ASD in offspring, we conducted a systematic review and meta-analysis of this issue. The aims of this study were to estimate the summary odds ratio for this association and have a comprehensive subgroup analysis to achieve more sufficient evidence of the association between disease severity and the risk of ASD.

MATERIALS AND METHODS {#s2}
=====================

This meta-analysis was conducted following the guidance provided in the Cochrane Handbook and was reported according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines \[[@R39]\].

Search strategy {#s2_1}
---------------

We performed a systematic electronic search in all available literature until Jun. 2017 on PubMed, EMBASE, Web of Science, PsycINFO database and China National Knowledge Infrastructure. We searched with the terms: "preeclampsia", "HDP", "hypertensive disorders of pregnancy", "hypertensive disorders in pregnancy", "hypertensive disorders complicating pregnancy", "pregnancy hypertension", "PIH", "pregnancy induced hypertension", "gestational hypertension", "gravid hypertension", "gravidic hypertension", "ASD", "autism spectrum disorder", "autism", "autistic disorder", "pervasive development disorders", "children", "childhood", "infantile". Searches were limited to human articles published in the English or Chinese. Two investigators inspected the titles and abstracts of citations and obtained the full texts. The search strategies are summarized in Figure [1](#F1){ref-type="fig"}. We also searched for additional relevant studies by browsing the bibliographies of the included trials and related reviews.

![Flow diagram of the studies selection process](oncotarget-09-1291-g001){#F1}

Inclusion and exclusion criteria {#s2_2}
--------------------------------

Studies were eligible if they: (i) were case--control studies, prospective studies, or RCTs; (ii) evaluated the association between HDP and ASD in offspring; (iii) presented relative risk (RR) or odds ratio (OR) estimates with 95% confidence intervals (CI) or necessary data for determination. Studies were excluded if they were (a) review articles, case reports, experimental studies, conference abstracts, animal studies or letters; (b) unpublished data; (c) lacked essential data for the pooled calculation. Two reviewers independently evaluated titles and abstracts of the identified articles and subsequently excluded those that were irrelevant.

Data extraction {#s2_3}
---------------

A pair of investigators independently carried out the data extraction. Disagreements were resolved by discussion, with input from other investigators. Data extracted from each study included: the first author's last name, year of publication, study location, study design, characteristics of study population (length of follow-up, sample size), number of ASD participants with or without HDP, effect sizes of the associations, covariates adjusted for in the analysis; diagnostic criteria of HDP and scoring of Newcastle-Ottawa Quality Assessment Scale (NOS).

Quality evaluation {#s2_4}
------------------

Quality evaluation of each included study was performed utilizing the Newcastle--Ottawa Scale (NOS) \[[@R40]\]. The assessment consisted of three major categories: selection (four items, one star for each), comparability (one item, up to two stars) and exposure (three items, one star for each). A maximum of nine stars can be given to one study. A final score of seven stars or more was regarded as high quality.

Statistical analysis {#s2_5}
--------------------

Stata version 12 (Stata Corporation, USA) was used for statistical analyses. Pooled odds ratios (OR) with 95% confidence intervals (CIs) between HDP and ASD were used to estimate effect sizes. The heterogeneity was assessed using both chi-squared test and I^2^ method \[[@R41]\]. When *P* value for chi-squared test was less than 0.10 or I^2^ was more than 50%, there was obvious heterogeneity among those included studies, and random-effect model was used to pool data. If there was no obvious heterogeneity among those included studies, a fixed-effect model was used to pool data. Subgroup analyses were stratified by clinical classification of HDP, maternal age, perinatal complications (preterm birth and premature rupture of membranes), maternal education, geographic area and gender of participants. Sensitivity analysis was performed by omitting one study by turns to test the changes of pooled ORs. Potential risk of publication bias was estimated by inspection of funnel plot. Publication bias was also assessed by Egger's test \[[@R42]\].

RESULTS {#s3}
=======

Literature search and study characteristics {#s3_1}
-------------------------------------------

Detailed search procedures are summarized in Figure [1](#F1){ref-type="fig"}. A total of 242 individual abstracts for potential studies were identified through literature search. 184 abstracts were excluded because they were irrelevant to the current meta-analysis. Of the 58 remaining clinical studies, 26 were further excluded for lacking of autism patients and 7 were letters, comments, editorials, or reviews, leaving 25 appropriate articles for full-text screening. We scrutinized the 25 articles and excluded 4 articles, including 2 exploring the association between HDP and schizophrenia and 2 showing outcomes as pregnancy complications. Thus, 21 studies with 6,527,652 unique participants met criteria for inclusion in the present meta-analysis. Among these 21 studies, 9 studies assessed the association between gestational hypertension and ASD, 11 assessed the relationship between pre-eclampsia and ASD, and the other 4 assessed the relationship between CHP and ASD. The detailed characteristics of these included studies are shown in Table [1](#T1){ref-type="table"}.

###### Characteristics of all identified studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference              year   location    Design                 Duration     sample size   HDP(+)/ASD(+)           HDP(+)/ASD(-)             OR (95%CI)                    adjustment for covariates                                                    Diagnostic criteria   NOS
  ---------------------- ------ ----------- ---------------------- ------------ ------------- ----------------------- ------------------------- ----------------------------- ---------------------------------------------------------------------------- --------------------- -----
  **Glasson EJ**         2004   Australia   Retrospective cohort   1980--1995   1778          33/465                  94/1313                   0.99 (0.66--1.50)             Gender, birth year, maternal age, PROM                                       ICD-9\                7
                                                                                                                                                                                                                                                           DSM                   

  **Buchmayer S**        2009   Sweden      Case-control           1987--2002   7296          **GH**: 21/1216\        **GH**: 90/6080\          GH: 1.04 (0.59--1.81)\        Maternal age, preterm birth, gender, birth year, delivery hospital           ICD-9\                8
                                                                                              **PE**: 39/1216         **PE**: 140/6080          PE: 1.64 (1.08--2.49)                                                                                      ICD-10                

  **Matsuishi T**        1999   Japan       Prospective cohort     1983--1987   223           2/18                    27/205                    NR                            Maternal age, PROM                                                           DSM-III-R             8

  **Stein D**            2006   Israel      Case-control           1970--1998   358           **GH**: 23/206\         **GH**: 17/152\           NR                            Gender, maternal education, maternal age, preterm birth, PROM                ICD-VIII\             5
                                                                                              **PE:** 11/206          **PE**: 18/152                                                                                                                       DSM-III\              
                                                                                                                                                                                                                                                           DSM-IV                

  **Larsson HJ**         2005   Denmark     Case-control           1972--1999   9464          11/364                  181/9100                  1.54 (0.83--2.86)             Child age, gender, birth year, preterm birth, maternal education             ICD-8\                7
                                                                                                                                                                                                                                                           ICD-10                

  **Burstyn I**          2010   Canada      Cohort                 1998--2004   216342        27/1122                 2747/215220               1.49 (1.00--2.23)             Maternal age, gender                                                         ICD-9                 7

  **Mann JR**            2010   America     Retrospective Cohort   1996--2002   87677         52/472                  5479/87205                NR                            Gender, maternal age and education, preterm birth                            ICD-9                 8

  **Walker CK**          2015   America     Case-control           2003--2011   867           **CHP**: 17/510\        **CHP**: 4/347\           NR                            Child age, gender, geographic area, maternal education                       ADI-R\                5
                                                                                              **Mild PE**: 23/408\    **Mild PE**: 9/277\                                                                                                                  ADOS                  
                                                                                              **Severe PE**: 26/408   **Severe PE**: 7/277                                                                                                                                       

  **Gillberg C**         1983   Sweden      Case-control           1962--1980   50            12/25                   6/25                      NR                            Gender; obestetric department                                                NR                    8

  **Dodds L**            2011   Canada      Retrospective cohort   1990--2002   129733        106/924                 11730/128809              1.24(1.02--1.52)              Gender, maternal age, preterm birth                                          ICD-9\                7
                                                                                                                                                                                                                                                           ICD-10                

  **Mason-Brothers A**   1990   America     Retrospective Cohort   1965--1984   285           17/225                  11/60                     NR                            Gender, PROM, maternal age                                                   DSM-III               5

  **Krakowiak P**        2012   America     Case-control           2003--2010   832           **CHP**: 19/517\        **CHP**: 4/315\           NR                            Gender, maternal age and education, ethnicity, preterm birth                 ADI-R\                7
                                                                                              **GH**: 148/517         **GH**: 61/315                                                                                                                       ADOS                  

  **Moore GS**           2012   America     Retrospective cohort   1991--2001   5979605       **CHP**: 201/21717\     **CHP**: 38158/5957888\   **CHP**: 1.45 (1.26--1.67)\   Gender, maternal age, ethnicity, birth order                                 ICD-9                 7
                                                                                              **PE**: 1249/21717      **PE**: 257401/5957888;   **PE**: 1.42 (1.29--1.57);                                                                                                       

  **Korzeniewski SJ**    2013   America     Case-control           1984--1987   177           5/12                    27/165                    NR                            Gender, birth year, birthweight, maternal age and education, preterm birth   NR                    6

  **Hadjkacem I**        2016   Tunisia     Case-control           2014--2014   101           5/50                    3/51                      NR                            Gender, maternal age, gender, preterm birth                                  DSM-V                 6

  **Bilder D**           2009   America     Case-control           1998--2002   13320         **CHP**: 1/120\         **CHP**: 63/13200\        **CHP**:1.752\                Gender, birth year                                                           DSM-IV-TR             7
                                                                                              **GH**: 7/120           **GH**: 524/13200         (0.241--12.738)\                                                                                                                 
                                                                                                                                                **GH**:1.466\                                                                                                                    
                                                                                                                                                (0.695--3.231)                                                                                                                   

  **Lyall K**            2012   America     Prospective cohort     1989--2003   66445         111/793                 6700/65652                NR                            Ethnicity, marital status,maternal age                                       NR                    5

  **Langridge AT**       2013   Australia   Retrospective cohort   1984--1999   5303          -/727                   -/4576                    1.25 (0.97, 1.61)             Gender                                                                       DSM-IIIR\             6
                                                                                                                                                                                                                                                           DSM-IV                

  **Polo-Kantola P**     2014   Finland     Case-control           1990--2005   5168          56/1036                 147/4132                  1.49 (1.10--2.10)             Gender, birth year, birth place, maternal age                                ICD-9\                7
                                                                                                                                                                                                                                                           ICD-10                

  **Hultman CM**         2002   Sweden      Case-control           1987--1994   2448          24/408                  76/2040                   1.6 (0.90--2.90)              Gender, birth year, and delivery hospital, maternal age, preterm birth       ICD-9                 7

  **Say GN**             2015   Turkey      Case-control           2015--2015   180           14/100                  6/80                      NR                            Age, gender                                                                  DSM-IV                5
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OR, odds ratio; NR, not referred; ICD, International Classification of Diseases; DSM, Diagnostic and Statistical Manual; ADI-R, Autism Diagnostic Interview-Revised; ADOS, Autism Diagnostic Observation Schedule; NOS, Newcastle-Ottawa Quality Assessment Scale; GH: Gestational hypertension; PE: Pre-eclampsia; CHP: Chronic hypertension complicating pregnancy; PROM: Premature rupture of membranes

Quality assessment {#s3_2}
------------------

All 21 eligible studies were assessed for quality according to the NOS. The quality of them varied from 5 to 8, with a mean of 6.57 (Table [2](#T2){ref-type="table"}). All studies were included in the subsequent analysis.

###### Appraisal of methodological quality (Newcastle-Ottawa Scale) of the including studies

  Study                  Case-cohort representative   Selection of non-exposed control   Ascertainment of exposure   Outcome negative at start   Comparability by design   Comparability by analysis   Outcome assessment   Duration of follow-up   Score
  ---------------------- ---------------------------- ---------------------------------- --------------------------- --------------------------- ------------------------- --------------------------- -------------------- ----------------------- -------
  **Glasson EJ**         ^\*^                         ^\*^                               ^\*^                        ^\*^                        ^\*^                      ^\*^                        ^\*^                 ×                       7
  **Buchmayer S**        ^\*^                         ^\*^                               ^\*^                        ^\*^                        ^\*^                      ^\*^                        ^\*^                 ^\*^                    8
  **Matsuishi T**        ^\*^                         ^\*^                               ^\*^                        ^\*^                        ^\*^                      ^\*^                        ^\*^                 ^\*^                    8
  **Stein D**            ^\*^                         ^\*^                               ^\*^                        ^\*^                        ×                         ^\*^                        ×                    ×                       5
  **Larsson HJ**         ^\*^                         ^\*^                               ^\*^                        ×                           ^\*^                      ^\*^                        ^\*^                 ^\*^                    7
  **Burstyn I**          ^\*^                         ^\*^                               ×                           ^\*^                        ^\*^                      ^\*^                        ^\*^                 ^\*^                    7
  **Mann JR**            ^\*^                         ^\*^                               ^\*^                        ^\*^                        ^\*^                      ^\*^                        ^\*^                 ^\*^                    8
  **Walker CK**          ^\*^                         ^\*^                               ^\*^                        ×                           ^\*^                      ^\*^                        ×                    ×                       5
  **Gillberg C**         ^\*^                         ^\*^                               ^\*^                        ^\*^                        ^\*^                      ^\*^                        ^\*^                 ^\*^                    8
  **Dodds L**            ^\*^                         ^\*^                               ^\*^                        ^\*^                        ×                         ^\*^                        ^\*^                 ^\*^                    7
  **Mason-Brothers A**   ^\*^                         ×                                  ^\*^                        ×                           ^\*^                      ^\*^                        ×                    ^\*^                    5
  **Krakowiak P**        ^\*^                         ^\*^                               ×                           ^\*^                        ^\*^                      ^\*^                        ^\*^                 ^\*^                    7
  **Moore GS**           ^\*^                         ×                                  ^\*^                        ^\*^                        ^\*^                      ^\*^                        ^\*^                 ^\*^                    7
  **Korzeniewski SJ**    ^\*^                         ×                                  ^\*^                        ^\*^                        ^\*^                      ^\*^                        ^\*^                 ×                       6
  **Hadjkacem I**        ^\*^                         ×                                  ×                           ^\*^                        ^\*^                      ^\*^                        ^\*^                 ^\*^                    6
  **Bilder D**           ^\*^                         ^\*^                               ^\*^                        ×                           ^\*^                      ^\*^                        ^\*^                 ^\*^                    7
  **Lyall K**            ^\*^                         ^\*^                               ×                           ^\*^                        ^\*^                      ×                           ^\*^                 ×                       5
  **Langridge AT**       ^\*^                         ^\*^                               ^\*^                        ^\*^                        ^\*^                      ×                           ^\*^                 ×                       6
  **Polo-Kantola P**     ^\*^                         ^\*^                               ×                           ^\*^                        ^\*^                      ^\*^                        ^\*^                 ^\*^                    7
  **Hultman CM**         ^\*^                         ^\*^                               ×                           ^\*^                        ^\*^                      ^\*^                        ^\*^                 ^\*^                    7
  **Say GN**             ^\*^                         ^\*^                               ^\*^                        ×                           ^\*^                      ×                           ^\*^                 ×                       5

^\*^ Indicates that a feature is present; ×, that a feature is absent. But for comparability by design this checklist awards a maximum of two stars (^\*\*^), one (^\*^) or none if the feature is completely absence(×).

Association of HDP with ASD in offspring {#s3_3}
----------------------------------------

After summarizing estimates from all available studies, there was a significant association between HDP and incidence of ASD (OR = 1.42, 95% CI: 1.34--1.50) (Figure [2](#F2){ref-type="fig"}), without obvious heterogeneity (*I*^2^ = 39.9%, *P* = 0.016).

![Forest plot of the correlation between HDP and ASD\
The mixed group include pre-eclampsia, gestational hypertension and chronic hypertension complicating pregnancy.](oncotarget-09-1291-g002){#F2}

Subgroup analysis {#s3_4}
-----------------

Significant associations were detected in almost all strata of subgroup analyses according to clinical classification of HDP, maternal age, perinatal complications (preterm birth and premature rupture of membranes), maternal education, geographic area and gender of participants. Results of subgroup meta-analyses are summarized in Table [3](#T3){ref-type="table"}.

###### Subgroup analysis of the association between HDP and ASD

                                                Studies   OR     95% CI
  --------------------------------------------- --------- ------ -------------
  **Clinical classification**                                    
  Gestational hypertension                      9         1.37   1.21--1.54
  Pre-eclampsia                                 11        1.43   1.31--1.55
  Chronic hypertension complicating pregnancy   4         1.48   1.29--1.70
  Mixed                                         3         1.37   1.13--1.67
  **Maternal age**                                               
  Higher in the case group                      7         1.44   1.33--1.55
  Match between case and control                7         1.29   1.11--1.50
  Lower in the control group                    2         1.42   1.16--1.73
  Not mentioned                                 4         1.50   1.22--1.84
  **Preterm birth**                                              
  Higher rate in the case group                 7         1.41   1.22--1.63
  Match between case and control                3         1.78   1.33--2.37
  Higher rate in the control group              1         1      0.51--1.95
  Not mentioned                                 10        1.41   1.32--1.51
  **Premature rupture of membranes**                             
  Higher rate in the case group                 1         0.82   0.18--3.76
  Match between case and control                3         0.92   0.66--1.28
  Higher rate in the control group              1         1      0.51--1.95
  Not mentioned                                 16        1.45   1.36--1.54
  **Maternal education**                                         
  Higher in the case group                      1         3.65   1.08--12.35
  Match between case and control                3         1.90   1.57--2.31
  Higher in the control group                   2         1.26   0.80--1.99
  Not mentioned                                 15        1.38   1.30--1.47
  **Geographic area**                                            
  Asia                                          3         1.18   0.70--1.99
  America                                       10        1.45   1.36--1.54
  Europe                                        6         1.46   1.16--1.84
  Africa                                        1         1.78   0.40--7.90
  Oceania                                       2         1.17   0.94--1.45
  **Gender of participants**                                     
  Male/female higher in case group              8         1.38   1.29--1.48
  Match                                         9         1.68   1.42--1.99
  Male/female higher in control group           0         \-     \-
  Not mentioned                                 4         1.44   1.19--1.74

The mixed group include pre-eclampsia, gestational hypertension and chronic hypertension complicating pregnancy.

Analysis of sensitivity and publication bias {#s3_5}
--------------------------------------------

Sensitivity analysis performed by omitting one study by turns showed all the pooled ORs were statistically significant (Figure [3](#F3){ref-type="fig"}). In addition, the funnel plot of this meta-analysis seemed to be symmetrical (Figure [4](#F4){ref-type="fig"}). And the Begg's test (*p* = 0.441) and Egger's test (*p* = 0.806) all suggested that there was not a possibility of publication biases that would influence the stability of the results.

![Sensitivity analysis of 21 studies included in this meta-analysis\
GH: Gestational hypertension; PE: Pre-eclampsia; CHP: Chronic hypertension complicating pregnancy.](oncotarget-09-1291-g003){#F3}

![Funnel plot of 21 studies included in this meta-analysis](oncotarget-09-1291-g004){#F4}

DISCUSSION {#s4}
==========

Currently, accumulating studies were performed to evaluate the relationship between pregnant complications and child neurodevelopmental disorders based on populations. A previous meta-analysis \[[@R43]\] conducted by Gardener in 2009, suggested that there is insufficient evidence to implicate any one prenatal factor in autism etiology, and non-significant association (OR = 1.01, 95% CI: 0.80--1.27) has been observed between pre-eclampsia/hypertension/edema and ASD. However, fourteen properly designed clinical trials were published from 2009 to 2017. Of these 14 studies, ten indicated a higher incidence of offspring ASD among HDP, while only 4 reported non-significance. Our meta-analysis update the previous review by covering the additional 9 years of publications, indicating that intrauterine exposure to HDP is associated with a 42% increase in the odds of ASD in the pooled estimate.

There is increasing evidence that maternal immune activation (MIA) is associated with a wide array of neurologic and psychiatric disorders \[[@R44], [@R45]\]. It is well documented that HDP, which is a state of MIA in itself, influences the fetal CNS development through inflammation. Subgroup meta-analyses defined by clinical classification of HDP revealed a slightly higher risk of pre-eclampsia (OR = 1.43) or CHP group (OR = 1.48) than gestational hypertension (OR = 1.37), suggesting the incidence of ASD might be correlated with disease severity. Our results showed that the maternal age may not be a confound factor in the main analysis. The rate of preterm birth was higher in case group, indicating it was a potential confounder in the analysis of HDP and ASD, as most HDP pregnancy must be terminated through cesarean section before full-term. The subgroup analysis of premature rupture of membranes and maternal education didn't provide powerful evidence due to the limited statistical information. On the other hand, we found that males increased the risk of ASD than females (with an increase in odds by as much as 38%), highlighting that sex-specific considerations will be crucial in exploring the underlying mechanism.

A meta-analysis \[[@R46]\] performed by Wang et al. in 2017 identified about 40 prenatal, perinatal, and postnatal factors which might increase the risk for ASD. However, these factors were examined individually. Therefore, it was still unclear that whether these factors are causal or play a secondary role in the development of autism. Moreover, although pre-eclampsia and gestational hypertension were identified as risk factors for autism in their study, these results were based on 3 or 5 studies, which had potential impact on the overall effect estimates. While in the present study, 9 and 11 studies were selected respectively to explore the association between gestational hypertension/pre-eclampsia and ASD, to draw a more reliable conclusion.

The strength of our meta-analysis, firstly, lies in its large sample size and comprehensive subgroup analysis, which allows a detailed examination of this association by stratifying the data according to clinical classification of HDP, maternal age, perinatal complications , maternal education, geographic area and gender of participants. Secondly, this study provides clinical evidence for the association between HDP and ASD in offspring, indicating that HDP may confer vulnerability to the fetal neurodevelopment. More clinical investigations are necessary to deeply investigate the mechanism, in the hope of illustrating the etiology of ASD and generating new therapies. Thirdly, the results from our sensitivity analyses suggest that our main results were credible to inclusion of studies and were not driven by a single study. There was insufficient statistical evidence of publication bias based on Egger's test. However, this meta-analysis also has some inherent limitations warranting discussion. First, blood pressure grade of HDP and drug treatment have been seldom mentioned in the included studies. Hence, the between-study heterogeneity of blood pressure or treatment strategy could be potential confounders precluding rigorous evaluation. Second, the pooled estimates were originated from 12 case-control, 7 retrospective cohort and only 2 prospective studies. The NOS scores of included studies range from 5 to 8, with a mean of 6.57, indicating moderate quality according to NOS scale (moderate quality scored 4--6). There is a compelling need for larger-size, multi-center and higher-quality prospective studies with unified criteria to obtain more persuasive conclusions. Finally, our meta-analysis is not suitable for worldwide generalizability due to the geographic restriction of the selected studies, which were mostly comprised of participants from America or Europe. Future clinical investigations performed in other regions are highly needed.

In summary, the present comprehensive meta-analysis suggests that intrauterine exposure to hypertensive disorders during pregnancy might be a risk factor for ASD in offspring. Identifying the infants most at risk for ASD is crucial to allow for preventative interventions from birth \[[@R47]\]. One intriguing possibility is making use of the placenta, a readily accessible tissue at birth but normally discarded, to serve as a non-invasive method to predict abnormal fetal brain development. It would be worthwhile to explore the association between placental pathologies and ASD of offspring in the future, which may lead to targeted surveillance or prevention approaches, in order to decrease the risk and incidence of ASD.
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